Nektar Therapeutics NKTR Gain On Sale Of The Huntsville Manufacturing Facility
Gain On Sale Of The Huntsville Manufacturing Facility at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:GainOnSaleOfTheHuntsvilleManufacturingFacility.
The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's gain on sale of the huntsville manufacturing facility.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's gain on sale of the huntsville manufacturing facility?
- Nektar Therapeutics (NKTR) reported gain on sale of the huntsville manufacturing facility of $0 in Q4 2025.
- How has Nektar Therapeutics's gain on sale of the huntsville manufacturing facility changed year-over-year?
- Nektar Therapeutics's gain on sale of the huntsville manufacturing facility decreased by 100.0% year-over-year, from $10.1M to $0.
- What does gain on sale of the huntsville manufacturing facility mean?
- This metric captures the net profit realized from the divestiture of manufacturing facilities or significant physical infrastructure. It represents a non-operating or peripheral gain that improves cash flow but does not reflect the recurring revenue-generating capability of the core business. Analysts evaluate this to understand the impact of capital recycling and asset optimization on the company's financial position.